Clinical Research
Cardiomyopathy
FcγReceptors IIa on Cardiomyocytes and Their Potential Functional Relevance in Dilated Cardiomyopathy

https://doi.org/10.1016/j.jacc.2006.11.051Get rights and content
Under an Elsevier user license
open archive

Objectives

The purpose of this study was to investigate how cardiac autoantibodies might contribute to cardiac dysfunction in patients suffering from dilated cardiomyopathy (DCM).

Background

In the majority of DCM patients, it is possible to detect antibodies with negative inotropic effect on cardiomyocytes. The manner in which these antibodies impair cardiac function is poorly understood.

Methods

Immunoglobulin (Ig)G was prepared from plasma of 11 DCM patients containing antibodies that induced a negative inotropic effect on cardiomyocytes. We analyzed the effects of antibodies/IgG fragments on calcium transients and on systolic cell shortening of adult rat cardiomyocytes and investigated the dependency of these effects on potential cardiomyocyte Fc receptors.

Results

In contrast to control subjects, intact IgG from DCM patients reduced calcium transients and cell shortening of cardiomyocytes. The F(ab′)2fragments of these antibodies did not induce these effects but inhibited the functional effects of DCM-IgG of the respective patients’ IgG. These effects were also inhibited by Fc fragments of normal IgG. Reconstitution of the Fc part by incubation of cardiomyocytes with DCM-F(ab′)2fragments followed by goat-anti-human-F(ab′)-IgG again induced reduction of cell shortening and of calcium transients. In rat and human ventricular cardiomyocytes, Fcγreceptors IIa (CD32) were demonstrated by immunofluorescence.

Conclusions

Our findings indicate that DCM-IgG-F(ab′)2bind to their cardiac antigen(s), but the Fc part might trigger the negative inotropic effects via the newly detected Fcγreceptor on cardiomyocytes. These results point to a novel potential mechanism for antibody-induced impairment of cardiac function in DCM patients.

Abbreviations and Acronyms

DCM
dilated cardiomyopathy
Ig
immunoglobulin

Cited by (0)

This study was supported in part by a grant from the Deutsche Forschungsgemeinschaft (SFB-TR 19) and by the Department of Cardiovascular Medicine.